Trial Profile

A clinical trial assessing dovramilast for the treatment of leprosy type 2 reaction

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2025 Status changed from planning to not yet recruiting as per Medicines Development for Global Health (MDGH) media release
30 Apr 2025 According to Medicines Development for Global Health (MDGH) media release, the USFDA cleared the companys Investigational New Drug (IND) Application for dovramilast and its global Phase 2 clinical trial may proceed in the United States to assess dovramilast in people with acute or recurrent leprosy type 2 reaction. The study is expected to begin by the end of Q3 2025, with sites in the United States, Philippines, Indonesia, Cote dvoire, Benin and Madagascar.
06 Mar 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com